Literature DB >> 15288477

Disruption of hepatocellular tight junctions by vascular endothelial growth factor (VEGF): a novel mechanism for tumor invasion.

Marcus Schmitt1, Axel Horbach, Ralf Kubitz, Andrea Frilling, Dieter Häussinger.   

Abstract

BACKGROUND/AIMS: Vascular endothelial growth factor (VEGF) is expressed by many tumors, including hepatocellular carcinoma (HCC) and is involved in tumor angiogenesis. Little is known about its role for HCC infiltration into normal liver parenchyma.
METHODS: The effects of VEGF on the integrity of tight junctions were studied in HepG2 cells and human HCC by means of confocal laser scanning microscopy.
RESULTS: VEGF induced within 45 min a marked loss of pseudocanaliculi and disruption of occludin-delineated tight junctions. This effect of VEGF was mimicked by phorbol-12-myristate-13-acetate (PMA) and was sensitive to protein kinase C (PKC) inhibition by Gö6850. VEGF induced within 15 min the translocation of the PKC alpha-isoform to the plasma-membrane, but had no effect on the activity of Erks and p38(MAPK). Sections from surgically removed HCC showed expression of VEGF in the tumor and occludin disassembly in normal liver parenchyma next to the tumor.
CONCLUSIONS: VEGF induces disruption of tight junctions in a PKC-alpha dependent manner. In addition to its known angioneogenic properties, VEGF may promote HCC spreading into normal liver parenchyma. The data may provide another rationale for the use of VEGF antagonists for tumor therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15288477     DOI: 10.1016/j.jhep.2004.04.035

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  32 in total

Review 1.  Current status of molecularly targeted therapy for hepatocellular carcinoma: basic science.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2010-05-27       Impact factor: 3.402

Review 2.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

3.  Hepatic tight junctions: from viral entry to cancer metastasis.

Authors:  Nikki P Lee; John M Luk
Journal:  World J Gastroenterol       Date:  2010-01-21       Impact factor: 5.742

4.  Novel antiangiogenic therapies against advanced hepatocellular carcinoma (HCC).

Authors:  R A Pazo-Cid; M Lanzuela; G Esquerdo; J L Pérez-Gracia; A Antón; G Amigo; J Martínez Trufero; A L García-Otín; P Martín-Duque
Journal:  Clin Transl Oncol       Date:  2012-07-18       Impact factor: 3.405

5.  Imaging predictors of the response to transarterial chemoembolization in patients with hepatocellular carcinoma: a radiological-pathological correlation.

Authors:  Sharon W Kwan; Nicholas Fidelman; Elizabeth Ma; Robert K Kerlan; Francis Y Yao
Journal:  Liver Transpl       Date:  2012-06       Impact factor: 5.799

Review 6.  Signaling Pathways as Potential Therapeutic Targets in Hepatocarcinogenesis.

Authors:  Yeliz Yılmaz; Ayşim Güneş; Hande Topel; Neşe Atabey
Journal:  J Gastrointest Cancer       Date:  2017-09

7.  Subgroup analysis of efficacy and safety of orantinib in combination with TACE in Japanese HCC patients in a randomized phase III trial (ORIENTAL).

Authors:  Hisashi Hidaka; Namiki Izumi; Takeshi Aramaki; Masafumi Ikeda; Yoshitaka Inaba; Kazuho Imanaka; Takuji Okusaka; Susumu Kanazawa; Shuichi Kaneko; Shinichi Kora; Hiroya Saito; Junji Furuse; Osamu Matsui; Tatsuya Yamashita; Osamu Yokosuka; Satoshi Morita; Hitoshi Arioka; Masatoshi Kudo; Yasuaki Arai
Journal:  Med Oncol       Date:  2019-05-03       Impact factor: 3.064

8.  Urothelial expression of neuropilins and VEGF receptors in control and interstitial cystitis patients.

Authors:  Ricardo Saban; Marcia R Saban; Julie Maier; Ben Fowler; Mark Tengowski; Carole A Davis; Xue-Ru Wu; Daniel J Culkin; Paul Hauser; Joseph Backer; Robert E Hurst
Journal:  Am J Physiol Renal Physiol       Date:  2008-09-24

9.  High expressions of vascular endothelial growth factor and platelet-derived endothelial cell growth factor predict poor prognosis in alpha-fetoprotein-negative hepatocellular carcinoma patients after curative resection.

Authors:  Jie Hu; Yang Xu; Zao-Zhuo Shen; Zheng Wang; Qing Lu; Guo-Huan Yang; Zheng-Bin Ding; Jia Fan; Jian Zhou
Journal:  J Cancer Res Clin Oncol       Date:  2009-04-07       Impact factor: 4.553

10.  Three-dimensional Huh7 cell culture system for the study of Hepatitis C virus infection.

Authors:  Bruno Sainz; Veronica TenCate; Susan L Uprichard
Journal:  Virol J       Date:  2009-07-15       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.